The study found that levels of cabotegravir were lower than those reported in clinical trials. Approximately half of all cabotegravir measurements in the study were below the target level.
Low drug concentrations do not automatically lead to virologic rebound in people receiving injectable treatment with cabotegravir and rilpivirine, Swiss researchers found in a study of people receiving injections for up to six months. They say they are uncertain why some people experience virologic rebound when they have low drug levels while others remain virologically suppressed, as well as why drug levels seem to be so much lower in everyday clinical practice than in clinical trials.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
-
[Press release] FDA grants priority review of New Drug Application for Gilead’s once-daily HIV treatment of bictegravir plus lenacapavir
-
[CROI 2026] HIV i-Base: Investigational HIV combinations – daily, weekly, 4- and 6-monthly…
-
[Press release] FDA approves Merck’s once-daily IDVYNSO™ (doravirine/islatravir)
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.